Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint - Fierce Biotech

By Anonymous User · February 21, 2026

Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint  Fierce BiotechA Cancer Detection Test Fails in Major Study  The New York TimesGrail shares plummet after cancer test falls short in three-year NHS study  firstwordpharma.comMulti-cancer blood test missed key goal in NHS trial  BBCThis once-hot cancer-detection company’s stock got cut in half after a failed trial  MarketWatch